Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based biotechnology company. The Company is engaged in developing new small molecule therapeutic approaches to improve the treatment of muscle diseases and disorders. The Company is focused on the research in muscle stem cell polarity into a proprietary discovery platform, called MyoReGenX, to identify degenerative muscle diseases where deficits in this process affect muscle regeneration and are amenable to therapeutic intervention. With this platform, the Company is building a pipeline of therapeutics to correct muscle stem cell polarity and promote the body’s innate muscle repair and regeneration process. The Company’s lead program is an oral, small molecule drug candidate in development as a potential disease-modifying treatment for Duchenne muscular dystrophy. It has wholly owned subsidiaries in Australia (Satellos Bioscience Australia Pty Ltd), in Canada (Amphotericin B Technologies, Inc.) and in Delaware, USA (Satellos Bioscience US, Inc.).


TSX:MSCL - Post by User

Bullboard Posts
Post by Steve888on Jan 22, 2017 3:00pm
171 Views
Post# 25738986

RE: Cheap shares won't last long

RE: Cheap shares won't last longGet on the boat at current share price of 0.04-0.045, I can sleep easy even with a few cents up or down.

ICO has enough cash for to last close to 1.5 years without dilution.  Think about that? It means that if anyone can buy the stock at say 4 or 5 cents and if it goes up even once in 1.5 years he has made money. Is that simple and clear?

I personally like the odds especially with the events and news thats to come anytime from now on.

Cash and equivalent $2.643 million without debts at the end of September 2016. 

"After the third quarter end, we also announced a world-wide exclusive option to a novel glaucoma candidate and we continue to discuss further complimentary additions to our ophthalmology pipeline with multiple parties. We estimate our runway to extend to Q2 2018 based on the current burn rate and we expect to report additional milestones during the remainder of 2016 and in early 2017". stated Andrew Rae, President and CEO (quoted from the financial report released in November 24, 2016).

Do your own d.d.


Bullboard Posts